BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Parkinson's Cure Journey//Expected readouts//EN
CALSCALE:GREGORIAN
X-WR-CALNAME:Parkinson's Cure Journey: expected Parkinson's trial results
BEGIN:VEVENT
UID:landmark-314-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261201
SUMMARY:Result expected: Low-dose lithium (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. A Buffalo te
 am is testing very low doses of lithium (a tenth of psychiatric doses) aga
 inst blood and MRI markers in four small studies of 15 to 35 people each\;
  the Phase 1 data are in and a randomised trial and its extension finish i
 n late 2026.
URL:https://clinicaltrials.gov/study/NCT04273932
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-282-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261201
SUMMARY:Result expected: Idebenone (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A small rand
 omised\, placebo-controlled Chinese trial tests whether idebenone delays p
 rogression from REM sleep behaviour disorder to Parkinson's or a related d
 isease\; the registry shows 28 people enrolled against 142 planned\, and n
 o results.
URL:https://clinicaltrials.gov/study/NCT04534023
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-294-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261201
SUMMARY:Result expected: TB006 (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. TrueBinding 
 is testing a monthly infusion of an antibody against galectin-3\, a sugar-
 binding protein that drives microglial inflammation\, in 62 people with ea
 rly Parkinson's\; enrolment is closed and the primary data are due about N
 ovember 2026.
URL:https://clinicaltrials.gov/study/NCT06773962
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-210-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20270101
SUMMARY:Result expected: N-DOSE (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. An 81-person
  dose-finding trial of up to 3\,000 mg a day of nicotinamide riboside fini
 shed in April 2025\, but no result has been located.
URL:https://clinicaltrials.gov/study/NCT05589766
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-182-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20270101
SUMMARY:Result expected: EXIST (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. BioArctic's 
 antibody that targets clumped (aggregated) alpha-synuclein finished a 38-p
 erson Phase 2a safety study in Parkinson's and multiple system atrophy in 
 August 2026\; BioArctic says safety looks good and full results are due in
  the second half of 2026\, and Phase 2b studies are planned for 2027 in ot
 her diseases.
URL:https://clinicaltrials.gov/study/NCT06671938
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-315-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270201
SUMMARY:Result expected: NAC (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A Philadelph
 ia group reports that intravenous plus oral NAC raised dopamine-transporte
 r scan signal by 3% to 8% and improved symptoms in two small trials with n
 o placebo\, and a 50-person follow-up using a different PET scan finishes 
 around January 2027.
URL:https://clinicaltrials.gov/study/NCT02445651
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-218-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270401
SUMMARY:Result expected: MOST-ABLE (Osaka) (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A 99-person 
 Japanese Phase 2 tests whether a daily semaglutide tablet slows motor decl
 ine\; no results yet.
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-76-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270401
SUMMARY:Result expected: ASPIRO (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. An uncontrol
 led Phase 1/2a trial of neurons grown from each patient's own cells report
 ed safe grafts and large motor gains in eight people at 12 months\, but no
 thing yet separates the cells from placebo effect.
URL:https://clinicaltrials.gov/study/NCT06344026
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-159-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270401
SUMMARY:Result expected: BEACON (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. After the LR
 RK2 inhibitor failed in broad early Parkinson's\, Denali is testing it in 
 people who carry a LRRK2 mutation\; data expected first half of 2027.
URL:https://clinicaltrials.gov/study/NCT06602193
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-158-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270401
SUMMARY:Result expected: exPDite-2 (Phase 3)
DESCRIPTION:Expected\, not promised: trials often report late. A sham-surge
 ry-controlled Phase 3 of lab-grown dopamine neurons in about 102 people\; 
 primary completion estimated March 2027.
URL:https://clinicaltrials.gov/study/NCT06944522
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-219-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270501
SUMMARY:Result expected: Radotinib (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A 43-person 
 French Phase 2 of the c-Abl blocker radotinib has finished dosing\; regist
 ry completion is April 2027.
URL:https://clinicaltrials.gov/study/NCT04691661
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-186-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270601
SUMMARY:Result expected: DAPA-PD (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A 36-person 
 placebo-controlled Phase 2 at Cambridge is testing whether an oral NLRP3 i
 nhibitor is safe and reduces inflammation in early Parkinson's\; it began 
 in February 2026 and is due to finish its main phase around May 2027.
URL:https://clinicaltrials.gov/study/NCT07157735
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-293-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270901
SUMMARY:Result expected: BHV-8000 (Phase 3)
DESCRIPTION:Expected\, not promised: trials often report late. Biohaven is 
 testing an oral drug that blocks two immune-signalling enzymes (TYK2 and J
 AK1) in 550 people with early Parkinson's\, with time to everyday-function
  worsening as the main measure.
URL:https://clinicaltrials.gov/study/NCT06976268
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-299-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20271001
SUMMARY:Result expected: REPLACE (Kenai) (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. Kenai Therap
 eutics is testing frozen\, donor-made dopamine progenitor cells in up to 1
 2 people in the US (REPLACE trial)\; the first patient was dosed in Decemb
 er 2025\, enrolment was announced complete in July 2026\, and no results e
 xist yet.
URL:https://clinicaltrials.gov/study/NCT07106021
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-220-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271201
SUMMARY:Result expected: NOSE-PD (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A 56-person 
 Phase 2 adds insulin to nasal glutathione\, after the glutathione-only tri
 al did no better than placebo.
URL:https://clinicaltrials.gov/study/NCT05266417
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-348-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20280101
SUMMARY:Result expected: UC San Diego trial (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. UC San Diego
  is running the first US test of the donor iPSC dopamine progenitors that 
 Kyoto tested in Japan\, in a seven-person open-label trial\; primary compl
 etion is estimated for December 2027.
URL:https://clinicaltrials.gov/study/NCT06482268
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-188-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20280101
SUMMARY:Result expected: NEULARK (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. After BIIB12
 2 failed in unselected early Parkinson's\, Neuron23's 150-person Phase 2 g
 ives a second LRRK2 inhibitor only to people whose disease a companion tes
 t flags as LRRK2-driven\; the main phase is due to finish around December 
 2027.
URL:https://clinicaltrials.gov/study/NCT06680830
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-301-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20280101
SUMMARY:Result expected: Mass General own-cell trial (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. Jeffrey Schw
 eitzer's team at Massachusetts General Hospital is repeating the 2020 one-
 patient graft of a person's own reprogrammed skin cells in a Phase 1 trial
  of up to eight people\; primary completion is estimated for December 2027
 .
URL:https://clinicaltrials.gov/study/NCT06687837
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-325-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280701
SUMMARY:Result expected: VacSYn (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. An improved 
 version of the PD01A vaccine produced antibodies in every one of 25 treate
 d people and entered spinal fluid\, but the first part was designed to tes
 t safety\, so whether it slows Parkinson's is unknown.
URL:https://clinicaltrials.gov/study/NCT06015841
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-160-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280901
SUMMARY:Result expected: REGENERATE-PD (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A sham-surge
 ry-controlled Phase 2 of a one-time GDNF gene therapy in moderate Parkinso
 n's\; primary completion estimated August 2028.
URL:https://clinicaltrials.gov/study/NCT06285643
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-347-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20290101
SUMMARY:Result expected: Brigham own-cell trial (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. A Mass Gener
 al Brigham team is grafting dopamine neurons made from each patient's own 
 blood cells into the brain in a 12-person Phase 1 trial\; the first patien
 t was treated in September 2024 and primary completion is estimated for De
 cember 2028.
URL:https://clinicaltrials.gov/study/NCT06422208
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-290-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20290101
SUMMARY:Result expected: TARBELA-PD (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. Roche plans 
 the largest placebo-controlled test yet of an NLRP3 inflammation blocker i
 n Parkinson's: 474 people with early disease\, with time to motor worsenin
 g as the main measure.
URL:https://clinicaltrials.gov/study/NCT07781644
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-321-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290301
SUMMARY:Result expected: ASPro-PD (Phase 3)
DESCRIPTION:Expected\, not promised: trials often report late. The only Pha
 se 3 test of whether a GCase-boosting drug slows Parkinson's: 330 people o
 n ambroxol or placebo for two years\, with a main readout expected around 
 2029.
URL:https://clinicaltrials.gov/study/NCT05778617
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-157-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290701
SUMMARY:Result expected: PARAISO (Phase 3)
DESCRIPTION:Expected\, not promised: trials often report late. The first Ph
 ase 3 of an anti-synuclein antibody\; about 900 people\, primary completio
 n estimated June 2029.
URL:https://clinicaltrials.gov/study/NCT07174310
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-287-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290701
SUMMARY:Result expected: ALN-SNCA (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. A first-in-h
 uman study of ALN-SNCA\, a drug that switches off the SNCA gene's messages
 \, is testing safety and spinal-fluid synuclein in 46 people with early Pa
 rkinson's\; it ends in mid-2029.
URL:https://clinicaltrials.gov/study/NCT07216066
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-225-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290901
SUMMARY:Result expected: PRISMS (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. The first re
 gistered placebo-controlled drug trial I could find that aims to stop peop
 le with REM sleep behaviour disorder from developing Parkinson's or Lewy b
 ody dementia\; the Path to Prevention platform trial is being set up along
 side.
URL:https://clinicaltrials.gov/study/NCT06996652
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-288-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300801
SUMMARY:Result expected: LY3962681 (Phase 1)
DESCRIPTION:Expected\, not promised: trials often report late. An siRNA inj
 ected into the spinal fluid is being tested for safety and for lowering sp
 inal-fluid alpha-synuclein in up to 124 people\, with Parkinson's patients
  required to have a positive seed-amplification test.
URL:https://clinicaltrials.gov/study/NCT06565195
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:landmark-326-readout@pdcurejourney.org
DTSTAMP:20261108T210848Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20310101
SUMMARY:Result expected: PreCoDe (Phase 2)
DESCRIPTION:Expected\, not promised: trials often report late. A planned T
 übingen Phase 2 gives the anti-synuclein antibody prasinezumab to people 
 with Parkinson's and a severe GBA mutation to see whether it slows loss of
  thinking skills\; registry shows it not yet recruiting.
URL:https://clinicaltrials.gov/study/NCT07055087
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR